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Objective: To determine if low frequency (100 Hz) pulsed subsensory threshold electrical stimulation
produced either through pulsed electromagnetic ﬁeld (PEMF) or pulsed electrical stimulation (PES) vs
sham PEMF/PES intervention is effective in improving pain and physical function at treatment
completion in adults with knee osteoarthritis (OA) blinded to treatment.
Method: The relevant studies were identiﬁed by searching eight electronic databases and hand search of
the past systematic reviews on the same topic till April 5, 2012.
We included randomized controlled trials (RCTs) of people with knee OA comparing the outcomes of
interest for those receiving PEMF/PES with those receiving sham PEMF/PES. Two reviewers indepen-
dently selected studies, extracted relevant data and assessed quality. Pooled analyses were conducted
using inverse-variance random effects models and standardized mean difference (SMD) for the primary
outcomes.
Results: Seven small trials (459 participants/knees) were included. PEMF/PES improves physical function
(SMD ¼ 0.22, 95% conﬁdence interval (CI) ¼ 0.04, 0.41, P ¼ 0.02, I2 ¼ 0%), and does not reduce pain
(SMD ¼ 0.08, 95% CI ¼ 0.17, 0.32, P ¼ 0.55, I2 ¼ 43%). The strength of the body of evidence was low for
physical function and very low for pain.
Conclusion: Current evidence of low and very low quality suggests that low frequency (100 Hz) pulsed
subsensory threshold electrical stimulation produced either through PEMF/PES vs sham PEMF/PES is
effective in improving physical function but not pain intensity at treatment completion in adults with
knee OA blinded to treatment. Methodologically rigorous and adequately powered RCTs are needed to
conﬁrm the ﬁndings of this review.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a degenerative disorder of the articular
cartilage associated with hypertrophic bone changes1. It is the most
common chronic joint disease and the leading cause of pain and
disability among older adults around the world2. Knee OA has an
immense public health impact due to the need for healthcare ser-
vices particularly if surgical replacement of the knee joint is
required3. In 2000, 25 million people in North America had knee
OA, and that number is expected to double by 2020 due to severalA. Negm, School of Rehabili-
1400 Main St. W., Hamilton,
.
med@yahoo.com (A. Negm),
r.ca (N.J. MacIntyre).
s Research Society International. Pfactors including sedentary life style, increasing prevalence of
obesity and population aging4.
Effective, conservative interventions for relieving pain and
improving physical function are needed for people with knee OA5.
Pulsed electromagnetic ﬁeld (PEMF) and pulsed electrical stimu-
lation (PES) are emerging non-pharmacologic conservative treat-
ments of knee OA. Both treatments produce pulsed electric
potentials below the sensory threshold either through an electro-
magnetic coil system (PEMF) or surface electrodes (PES) applied
around the knee joint6e8. These subsensory-threshold pulsed
electric potentials stimulate intrinsic potentials9, which alter the
homoeostatic balance of cartilagematrix degradation and synthesis
in favour of cartilage repair10. In cell culture and animal studies,
electrical stimulation similar to that produced by PEMF/PES in-
creases cartilage synthesis by down regulation of interleukin-1 (IL-
1) and up regulation of transforming growth factor beta (TGFb)ublished by Elsevier Ltd. All rights reserved.
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can content in the cartilage matrix and enhanced chondrocyte
proliferation11. In an animal model study, PES of less than 100 Hz
has shown higher efﬁcacy than frequencies of 150 Hz or more12.
Moreover, higher frequencies have been associated with harmful
changes in bone tissue6.
Previous systematic reviews have addressed the question of
efﬁcacy of PEMF and PES for knee OA management and reached
contradicting conclusions13,14. McCarthy et al. (2006) pooled data
from ﬁve randomized controlled trials (RCTs) (276 participants/
knees) and concluded that PEMF and PES are not effective for knee
OA pain or physical function13; Vavken et al. (2009) pooled data for
nine RCTs (483 participants/knees) and concluded that PEMF and
PES might improve physical function but not pain in the knee OA
population at treatment completion14. A systematic review con-
ducted byWe et al. searched literature published to December 2011
to determine the efﬁcacy of PEMF pooling data from 14 studies (930
participants/knees) reporting knee OA pain and physical function
outcomes at 4, 8, 12, and 16 weeks15. Similar to the conclusions
reported by Vavken et al. (2009), We et al. reported that physical
functionwas improved at 8 weeks with active PEMF (ﬁve trials, 304
participants/knees; all interventions completed at 6 weeks) and
painwas not signiﬁcantly improved at any time point (maximum of
11 trials, 762 participants/knees (at 4 weeks) in which the inter-
vention period was 2, 3, 4, or 6 weeks). However, the inclusion of
trials in which pulsed subsensory threshold electrical stimulation
was applied at higher frequencies than that expected to be bio-
logically beneﬁcial to participants with and without knee OA who
were not blinded and/or not randomized to treatment leaves the
question of efﬁcacy unresolved.
Objective
The objective of this systematic review was to determine if low
frequency (100 Hz) pulsed subsensory threshold electrical stimu-
lation produced either through PEMF/PES vs sham PEMF/PES inter-
vention is effective in improving pain and physical function at
treatment completion in adults with knee OA blinded to treatment.
Adverse events were the primary safety outcome. Secondary out-
comes included patient global assessment, imaging-based knee joint
status, health-related quality of life and physician global assessment.
Methods
The Cochrane Collaboration methodology was followed20 in the
conduct of this review and PRISMA guidelines were followed for
reporting the methods and results of this systematic review and
meta-analysis21.
Eligibility criteria and search strategy
Studies were included if: (1) participants with clinically and/or
radiological conﬁrmed knee OA; (2) PEMF/PES frequency was
100 Hz; (3) Comparator is sham PEMF/PES; (4) primary outcome
was pain and/or physical function; (5) the study design is RCT with
blinded participants; (6) data for knee OA participants were re-
ported independently pre- and post-treatment; and (7) partici-
pants were over 30 years of age. Studies were excluded if: (1)
results were reported in another trial; (2) published data were
insufﬁcient for meta-analysis and corresponding authors did not
respond to requests for further information; (3) co-interventions
were applied to only one group; and (4) the trial was written in a
language other than English.
The relevant studies were identiﬁed by searching ﬁve electronic
databases: MEDLINE, CINAHL, EMBASE, CENTRAL and AMED. Thesearch strategy combined medical subject headings (MeSH) and
text terms describing knee OA with terms describing PEMF/PES.
The search was limited to English language, human, adult, and RCT.
The keywords and MeSH used for each of the databases and the
search results are shown in Appendix A. We searched three clinical
trial registries to identify ongoing trials: Clinical Trials Registry,
Current Controlled Trials and the World Health Organisation In-
ternational Clinical Trials Registry Platform. Hand search of the past
systematic reviews on the same topic was performed. The last
search was run on April 5, 2012.
Study selection
The eligibility assessment of title and abstract of citations ob-
tained from the search was performed by two independent re-
viewers (AN, AL) unblinded to author, journal and country. Any
disagreement was resolved through consensus. After title and ab-
stract screening for potentially eligible studies, two reviewers (AN,
NM) checked the full text articles for eligibility independently and
any disagreements were resolved through consensus. The agree-
ment between the two reviewers was assessed by examining raw
agreement and unweighted kappa (k).
Data extraction and management
A data extraction form was developed for this review and pilot-
tested independently on three randomly-selected studies by two
reviewers (AN, NM) to ensure consistency in extraction. The
extraction formwas reﬁned accordingly and data were extracted in
duplicate. Six authors were contacted for further information, two
authors responded and one provided numerical data that were
presented graphically in the published paper18. The extracted in-
formation included the characteristics of participants (age, gender,
knee OA severity and method of diagnosis), PEMF/PES (the device,
application and treatment protocol), and the type of outcome
measures, baseline data, post-treatment data, and change means
and standard deviations (SDs) or the information from which SD
could be derived, such as standard error or conﬁdence interval (CI).
When a trial presented outcomes at more than one time point, data
for all time points were extracted; however, only data acquired
immediately post-treatment were used in the meta-analysis.
Assessment of risk of bias for included studies
Two reviewers (AN, NM) independently assessed risk of bias for
each study according to the Cochrane Handbook (chapter 8) for
eight domains: sequence generation, allocation concealment,
blinding of participants and care givers, blinding of outcome as-
sessors, completeness of outcome data, completeness of outcome
reporting and the potential for other threats to the validity of the
study21. Any disagreement regarding risk of bias was resolved by
consensus. Risk of publication bias was examined using a funnel
plot of each study’s effect estimates for the primary outcomes
against their standard error; no statistical test was performed.
Data synthesis
The outcomes in the included studies reported continuous data
(mean and SD) and used different outcome measures for each
outcome with the exception of patient and physician global as-
sessments, therefore, standardized mean differences (SMDs) were
used to estimate the treatment effect to facilitate comparisons
across all outcomes. Change means and SDs were pooled to adjust
for the baseline differences between groups in each study. Three
studies22e24 reported post-treatment means and SDs. Therefore,
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Cochrane Handbook21. Relative risk (RR) and 95% CIs for the re-
ported side effects were calculated.
One study22 did not report post-treatment SDs for the outcomes
(required to calculate change SD). Furthermore, calculating the SD
from the study data was not possible since other important sta-
tistics (standard error, CI, or exact P-values) were not provided.
Baseline SDs were used instead of post-treatment SDs based on the
assumption that the intervention does not change the variability
between groups21. SMDs were pooled and the inverse-variance
random effects model was used considering the variability across
studies21. Review Manager Version 5 was used for data analysis
(http://ims.cochrane.org/revman). CIs at the 95% level (95% CI)
were calculated for pooled estimates for each outcome and the Z
test was used to determine the treatment effect. Statistical signiﬁ-
cance was considered at P < 0.05.
Investigation of heterogeneity and subgroup analysis
Heterogeneity among the included studies was measured using
the chi-squared test (c2). For c2 values with P < 0.1, heterogeneity
was considered to be signiﬁcantly high. The I2 was used to assess
the inconsistency between the pooled studies. The I2 of <60% was
considered to be acceptable for pooling the data across the
studies21.
The pulsed subsensory threshold electrical stimulation types,
treatment duration and source of funding were hypothesized to
generate heterogeneity across the studies. Therefore subgroup
analyses were planned a priori for the different types of pulsed
subsensory threshold electrical stimulation (PES and PEMF),
treatment durations (<12 weeks and 12 weeks) and source of
funding (non-industry and industry).
Grading of evidence
Two reviewers (AN, NM) graded the strength of the body of
evidence that emerged from this review using the Gradepro pro-
gram25. Five domains were assessed: risk of bias, inconsistency of
the results, indirectness of the outcome, imprecision of the results
and publication bias.Fig. 1. Flow diagram for identiﬁcation of eligibSensitivity analysis
To ensure the robustness of the pooled outcomes, post-hoc
sensitivity analyses were conducted by repeating the meta-
analyses after removing data from each of the three studies for
which the change SD was imputed22e24.
Results
Figure 1 shows the ﬂow diagram for identiﬁcation of eligible
trials. After title and abstract screening, 11 studies were retrieved
for full text review. Seven studies met the eligibility criteria. The
raw agreement between the reviewers in identifying the full text
studies for inclusion in this review was 100% (k ¼ 1).
Description of included studies
Seven parallel group randomized placebo controlled studies
published between 1994 and 2011 were included. Two trials were
conducted in USA17,26, two in Turkey22,23, and one in each of
Denmark24, Australia18 and the UK27. The duration of the inter-
vention varied from 2 to 26 weeks and the frequency of PEMF/PES
ranged from 5 to 100 Hz. The control groups in all the studies used
sham devices. In total, the studies included 459 participants with
an average age of 63.7 years and with greater proportion of females
compared to males. The description and characteristics of the
included studies are summarized in Table I.
Description of excluded studies
After the full-text eligibility assessment, four studies were
excluded28e31 for various reasons. The RCT by Zizic et al. (1995) was
excluded because the SDs or other important statistics (standard
error, CI, or exact P-values) were not provided26. In the trial by
Jacobson et al. (2001), radiological or clinical criteria for diagnosing
knee OAwas not reported and SDs for means were not provided for
the intervention and placebo groups29. Nicolakis et al. (2002) used
PEMF but with frequencies exceeding 100 Hz30. Lastly, Trock et al.
(1993) includedﬁveparticipantswithhandOA, oneparticipantwith
ankle OA and 21 participants with knee OA and the results for kneele trials evaluating the effect of PEMF/PES.
Table II
Methodological quality of included studies
Trials Random
sequence
generation
Key domains Overall risk
of bias
Allocation
concealment
Blinding of
participant
Blinding of
care provider
Blinding of
outcome
assessor
Incomplete
outcome data
Selective
reporting
Other
bias
Trock et al.26 Low* Low* Low* Highy Low* Highy Low* Low* Highy
Pipitone and Scott27 Low* Low* Low* Low* Low* Low* Highy Low* Highy
Thamsbor et al.g24 Unclearz Unclearz Low* Unclearz Low* Low* Low* Low* Unclearz
Garland et al.17 Highy Highy Low* Low* Low* Low* Low* Unclearz Highy
Ay and Evcik23 Highy Unclearz Highy Highy Low* Low* Low* Unclearz Highy
Özgüçlü et al.22 Low* Highy Low* Highy Low* Low* Highy Low* Highy
Fary et al.18 Low* Low* Low* Low* Low* Low* Low* Low* Low*
* Low risk of bias.
y Unclear if high or low risk of bias.
z High risk of bias.
Table I
Characteristics of participants and interventions in the included studies
Study Sample size
(N)
Age, y (mean (SD)) Female (%) Intervention
PEMF/PES Control PEMF/PES Control PEMF/PES Control Type Frequency (Hz) Total exposure
(Hs  Session/Week)
Duration
(Weeks)
Trock et al.26 40 44 69.2 (11.5) 65.8 (11.7) 69 70.5 PEMF 5e12 0.5  3-5 4e6
Pipitone and Scott27 34 35 62 64 35 20 PEMF 3e20 0.5  7 6
Thamsborg et al.24 42 41 60.4 (8.7) 59.6 (8.6) 47.6 60.9 PEMF 50 2  5 6
Garland et al.17 39 19 64.3 (10.2) 69.9 (11.4) 69.2 57.9 PES 100 7  7 12
Ay and Evcik23 30 25 58.9 (8.8) 57.7 (6.5) 70 76 PEMF 50 0.5  5 3
Özgüçlü et al.22 20 20 60.6 (7.7) 62.2 (8.2) NR NR PEMF 50 0.5  5 2
Fary et al.18 34 36 70.7 (8.9) 68.9 (11.4) 50 44 PES 100 7  7 26
NR, Not reported.
Fig. 2. Funnel plot for the seven included studies for the pain outcome.
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these authors to get the required information to include these
studies but they did not reply.
Risk of bias in the included studies
Table II summarizes the risk of bias assessment for the seven
included studies. The overall methodological quality assessment
indicated that risk of bias was low in one study18, unclear in
another24 and high in the other ﬁve studies17,22,23,26,27. As a result,
risk of bias across the studies is high. The raw agreement between
the reviewers in evaluating the risk of bias domains was 89.5%
(k ¼ 0.81). Publication bias was not detected in the funnel plots of
the primary outcomes, since they are relatively symmetrical as
shown in Fig. 2 for pain.
Effects of interventions
Table III demonstrates an overall summary of the effects of PEMF
and PES on all outcomes of interest.
Primary outcomes
In seven RCTs included for meta-analysis, pain was assessed in a
total of 459 participants randomized to an active PEMF/PES group
(n ¼ 239) and a placebo PEMF/PES group (n ¼ 220). No difference
between groups was observed (SMD ¼ 0.08, 95% CI: 0.17, 0.32,
P ¼ 0.55) as illustrated in Fig. 3. Overall, the strength of the body of
evidence for the pain outcome was judged to be very low for rea-
sons described in Table III.
Figure 4 illustrates the beneﬁcial effect of PEMF/PES on physical
function (SMD ¼ 0.22, 95% CI: 0.04, 0.41, P ¼ 0.02) in 456 of the
participants with knee OA enrolled in the seven RCTs. See Table III
for the summary of ﬁndings for this outcome including the ratio-
nale for judging the strength of the body of evidence as low.Heterogeneity due to pulsed subsensory threshold electrical
stimulation types, treatment regimens and sources of funding was
hypothesized to inﬂuence treatment effect. Five studies used PEMF
devices and two studies used PES devices (see Table I). Treatment
duration was 12 weeks in two studies and <12 weeks in ﬁve
studies (see Table I). Three studies were funded by industry17,26,27,
two were federally funded18,24 and two studies did not report the
source of funding22,23. The results of subgroup analyses for pain and
physical function outcomes are shown in Table IV.
Adverse events
Four studies reported few, self-limited adverse events, such as
temporary increase in knee pain, foot numbness and paraesthesia,
and sensation of warmth. The risk ratio was calculated for mild
knee skin rash that was reported two studies (RR ¼ 0.96, 95% CI:
Table III
Summary of Findings
Outcomes SMD and RR (95% CI) compared
to the control group
Sample Size
(no. of studies)
Quality
of the
evidence*
Inconsistency, I2y Heterogeneity,
c2, P valuez
Outcome speciﬁc
risk of bias
Pain reduction
VAS26,23 and WOMAC
pain subscale17,18,22,24,27
Follow-up: 2e26 weeks
0.08 SD higher (0.17 to 0.32) 459 (seven
studies)
Very lowx 43% 0.1 High risk of bias of the
included studies, high
results’ heterogeneity,
small sample size and
wide CI
Physical function
WOMAC physical
function17,18,22,24,27
lequesne index23 ADL26
Follow-up: 2e26 weeks
0.22 SD higher (0.04e0.41) 456 (7 studies) Lowx 0% 0.45 High risk of bias of the
included studies, small
sample size and wide CI
Adverse event
Skin rash17,18
Follow-up: 12e26 weeks
RR 0.96 (0.45e2.03) 128 (2 studies) Very lowx 0% 0.78 High risk of bias in the
included studies, very
small sample size and
wide CI
Patient global assessment
VAS17,18,26
Follow-up: 6e26 weeks
0.26 SD higher (0.14, 0.66) 209 (3 studies) Very lowx 61% 0.08 High risk of bias of the
included studies, results’
inconsistency, small sample
size and wide CI
Quality of life
SF3618 and EQOL27
Follow-up: 6e26 weeks
Highly heterogeneous result 139 (2 studies) Very lowx 84% 0.01 High results’ heterogeneity,
small sample size and
wide CI
Physician global assessment
VAS26
Follow-up: 6 weeks
0.46 SD higher (0.02, 0.90) 81 (1 study) Very lowx Only one
study included
Only one
study included
High risk of incomplete
data in the included study,
very small sample size and
wide CI
VAS, Visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; ADL, Activity of daily life questionnaire; EQOL, Euro-quality of life
questionnaire.
* GRADE Working Group grades of evidence, High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect. Moderate quality: Further
research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an
important impact on our conﬁdence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
y jInconsistency across studies; up to 40%, might not be important; 30e60%, may represent moderate heterogeneity; 50e90%, may represent substantial heterogeneity.
z Chi-square P value; <0.1, statistical signiﬁcant heterogeneity; 0.1, non-signiﬁcant heterogeneity.
x Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate. Very low quality:
We are very uncertain about the estimate.
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between the experimental and placebo groups in terms of skin
rash; however, the strength of this body of evidence was very low
as described in Table III.
Secondary outcomes
No RCT reported imaging-based knee joint status outcomes.
Table III summarizes the pooled estimates of effects on health-
related quality of life and physician global assessment. Figure 6
shows the pooled estimate for effect on patient global assessment
reported in three trials (209 participants/knees). As summarized in
Table III, precision of the estimate is low (95% CI: 4.39, 18.77) and
inconsistency is high.
Sensitivity analyses
The pooled estimates were unchanged by the removal of each
study in which change SDs was imputed22e24.Fig. 3. Forest plot for meta-analysis of the effect of pulseQuality of evidence
The strength of the body of evidence was assessed using the
criteria recommended by the GRADE Working Group25. The
strength of the body of evidence of all outcomes was reduced by
high risk of bias, small sample size (imprecision) and inconsistency
of the results (high I2 value). The strength of the body of evidence is
low for physical function and very low for the other outcomes.
Discussion
The main ﬁnding of this systematic review and meta-analysis is
that PEMF/PES treatment improves physical function but does not
decrease pain signiﬁcantly in people with knee OA. Heterogeneity
was not a signiﬁcant problem for pain or physical function out-
comes and subgroup analyses show that the effect estimates are
similar regardless of the type of pulsed subsensory threshold
electrical stimulation (PEMF and PES) and length of treatment (<12d PEMF/PES compared to sham treatment on pain.
Fig. 4. Forest plot for meta-analysis of the effect of PEMF/PES compared to sham treatment on physical function.
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outcomes in the three studies funded by industry were larger and
more inconsistent compared to the four studies that were not
funded by industry. The strength of the body of evidence is low for
physical function indicating that further research is very likely to
have an important impact on our conﬁdence in the effect estimate
and is likely to change the estimate. The very low strength of the
body of evidence regarding the effect on pain creates great uncer-
tainty about the estimate and future research is expected to change
the estimated effect.
The proposed mechanism of action of PEMF and PES is to
enhance articular cartilage regeneration10. Because articular carti-
lage is poorly innervated and vascularized, it follows that this
intervention may not decrease knee OA pain. Pain is perceived due
to stimulation of unmyelinated and small myelinated nerve ﬁbres
in the joint and surrounding tissues such as the joint capsule, lig-
aments, synovium, bone and the outer edge of the menisci32.
Moreover, central sensitization (hyperexcitability of neurones in
the central nervous system) has been observed in people with
chronic pain due to knee OA33. Chronic pain is a multidimensional
problem34 resulting in changes in brain areas active in sensori-
motor function, affect and cognition32. Even if future research
demonstrates that PEMF/PES have a small effect on pain, this effect
may be of minimal clinical signiﬁcance without a corresponding
intervention that addresses changes in the central nervous system.
All reported adverse events were mild and self-limited. Skin
rash was the most frequently reported adverse event and rates
were similar for both the active and sham PEMF/PES stimulation
groups. The two studies that reported skin rash used PES devices
and the longest treatment session (7 h daily). Therefore, skin rash
may be a problem for people using the PES device or may be related
to the duration of contact between the electrodes and the skin. As a
result, caution is warranted when applying the PES device to the
knee of people prone to skin irritation. Overall, low frequency
PEMF/PES appears to be safe for use in people with knee OA.
Few studies reported on our secondary outcomes of interest.
Patient global assessment was reported in three studies and thereTable IV
Summary of SMD, inconsistency (I2), and heterogeneity (c2, P value) on subgroup analys
Subgroup analyses Pain
SMD (95% CI) I2* c2
Type
PEMF22e24,26,27 0.08 (0.19, 0.35) 36% 0.
PES17,18 0.09 (0.67, 0.85) 77% 0.
Treatment duration
12 Weeks17,18 0.09 (0.67, 0.85) 77% 0.
<12 Weeks22e24,26,27 0.08 (0.19, 0.35) 36% 0.
Funding
Industry17,26,27 6.63 (2.66, 15.91) 74% 0.
Non-industry18,22e24 0.32 (0.92, 0.28) 0% 0.
* Inconsistency across studies; up to 40%, might not be important; 30e60%, may repr
y Chi-square P value; <0.1, statistical signiﬁcant heterogeneity; 0.1, non-signiﬁcantwas no difference between groups. Only two studies reported
health-related quality of life and the pooled studies were highly
heterogeneous (Table III). Physician global assessment was re-
ported in a single study that showed the effectiveness of PEMF/PES
in improving this outcome. However, we have to interpret the
improvement in physician global assessment with caution because
the study was small and of low quality (Table III). No study reported
imaging-based knee joint status outcomes. High quality studies are
needed to evaluate the effectiveness of PEMF/PES on knee joint
status, physician global assessment; patient global assessment and
health-related quality of life.
Follow-up rates across the included studies ranged from 75% to
100% and studies reported compliance rates varying from 63% to
75%. These rates for follow-up and compliance suggest that PEMF/
PES has acceptable tolerability in the knee OA population. Consid-
ering that three of the included studies used self-applied devices,
PEMF/PES may be a useful self-management tool for people with
knee OA to improve physical function.
Our ﬁndings conﬁrm and extend those reported in the meta-
analysis conducted by Vavken et al. (2009)14 and We et al.
(2012)15. Our review includes data for an additional 128 partici-
pants/knees that were not reported in the other reviews. Moreover,
our study had important differences in methodology that provide
greater conﬁdence in the estimates of effect. The review by Vavken
et al. (2009) included high and low frequency PEMF/PES and we
excluded studies that used high frequency PEMF and did not report
outcomes for participants with knee OA separate from those with
hand and ankle OA. Vavken et al. (2009) used the end point clinical
scores andweightedmean difference to combine scores of different
scales in their statistical analysis, which is inappropriate. We used
the change mean to balance any differences in baseline values be-
tween the study groups and SMD to combine scores of different
scales. We et al. (2012) included trials administering either high or
low frequency PEMF and did not perform subgroup analysis based
on frequency. Sixteen sensitivity analyses were reported to deter-
mine efﬁcacy on pain at 4 weeks (0e2 weeks prior to completion of
the intervention) and 8 weeks (2 weeks following completion ofes for pain and physical function outcomes
Physical function
, P valuey SMD (95% CI) I2* c2, P valuey
18 0.24 (0.02, 0.46) 0% 0.70
04 0.21 (0.47, 0.89) 71% 0.06
04 0.21 (0.47, 0.89) 71% 0.06
18 0.24 (0.02, 0.46) 0% 0.70
02 3.65 (0.57, 6.73) 33% 0.23
47 0.37 (1.20, 1.94) 0% 0.79
esent moderate heterogeneity; 50e90%, may represent substantial heterogeneity.
heterogeneity.
Fig. 5. Forest plot for meta-analysis of the effect of PEMF/PES compared to sham treatment on adverse events (skin rash).
Fig. 6. Forest plot for meta-analysis of the effect of PEMF/PES compared to sham treatment on patient global assessment.
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priori35. Two of low frequency PEMF trials included in the review by
We et al.15 were excluded from our systematic review because of
our eligibility criteria (lack of participant blinding and English
language limit). Despite these differences, the main results
regarding efﬁcacy of PEMF/PES on physical function, but not pain,
are consistent.
The methodological rigour adopted in the review process is the
main strength of this meta-synthesis. For example, a comprehen-
sive search strategy and duplicate assessment of eligibility,
extraction of data, assessment of risk of bias and judgement of the
strength of the body of evidence were conducted. A data extraction
form was developed and piloted for consistency between the two
reviewers extracting data from the studies. In contrast to the overall
risk of bias, six of the included studies had a low risk of bias due to
blinding of participants and all seven included studies had low risk
of bias due to blinding of outcome assessors. This is critical to the
validity of the estimated effects on outcomes since lack of blinding
is likely to inﬂate the effect size36. These factors are strengths in our
review; we hypothesize that inclusion of future larger trials will
increase the conﬁdence that PEMF/PES is effective for improving
physical function and a small effect on pain may emerge.
Limitations need to be considered in interpreting the results of
our review. At the level of the included trials, there is variability in
treatment duration, number of sessions, treatment setting (where
the treatment was provided and by whom), frequency, reported
units and other parameters of PEMF/PES. Furthermore, no trials
reported dose parameters at the skin surface. Therefore, we are
unable to determine the therapeutic window or recommend a
speciﬁc treatment protocol for administrating PEMF/PES. The small
number and size of trials precluded focussing inclusion criteria
further. Five of the seven included trials had a high risk of bias. Few
to no studies collected data related to our secondary outcomes of
interest. To examine the proposed mechanism of PEMF/PES on
enhancing cartilage regeneration, future studies need to include
outcome measures that detect cartilage metabolism or change in
morphology. At the review level, our literature search was limited
to the English language which may have excluded relevant litera-
ture and bias the results. Some studies were excluded from our
review due to missing methodological and statistical details;
therefore, we urge future publications of RCTs to follow the CON-
SORT statement reporting guidelines for non-pharmacologic
treatments37.Conclusion
Our results suggest that low frequency (100 Hz) pulsed sub-
sensory threshold electrical stimulation produced either through
PEMF/PES vs sham PEMF/PES is effective in improving physical
function but not pain intensity at treatment completion in adults
with knee OA blinded to treatment. We cannot give a conclusion
about the effect of this treatment on the secondary outcomes due to
the small numbers of studies that reported them. PEMF/PES is
associated with few, self-limited adverse events such as skin rash.
More studies are needed to conﬁrm and extend the ﬁndings of this
systematic review.
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Appendix A
Search strategies
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations and Ovid MEDLINE(R) <1946 to week 1 April 2012>
1 exp Electric Stimulation Therapy/or Pulsed electrical stimula-
tion treatment.mp. (52016)
2 electromagnetics.mp. or exp Electromagnetic Phenomena/
(308044)
3 electromagnetic$.tw. (18146)
4 exp electric stimulation therapy/ (52016)
5 electrical stimulation.tw. (34065)
6 exp Electromagnetic Phenomena/or exp Electric Stimulation
Therapy/or exp Electromagnetic Fields/or pulsed electro-
magnetic.mp. or exp Magnetic Field Therapy/ (363141)
7 osteoarthritis.mp. or exp Osteoarthritis/or exp Osteoarthritis,
Knee/ (47206)
A. Negm et al. / Osteoarthritis and Cartilage 21 (2013) 1281e128912888 Knee osteoarthritis.mp. or exp Osteoarthritis, Knee/ (8830)
9 exp Osteoarthritis/or gonarthrosis.mp. or exp Osteoarthritis,
Knee/ (38215)
10 1 or 2 or 3 or 4 or 5 or 6 (401885)
11 7 or 8 or 9 (47510)
12 10 and 11 (414)
13 limit 12 to (english language and humans and randomized
controlled trial) (78)
Database: Embase <1974 to 2012 April>
1 Electric Stimulation Therapy.mp. or exp electrostimulation
therapy/ (147605)
2 Electromagnetics.mp. or exp electromagnetic ﬁeld/ (15534)
3 Electromagnetic Phenomena.mp. or exp electromagnetic
ﬁeld/ (15496)
4 Electromagnetic.mp. or exp electromagnetic ﬁeld/ (28950)
5 electric stimulation therapy.mp. or exp electrostimulation
therapy/ (147605)
6 Electrical stimulation.mp. or exp electrostimulation/ (89918)
7 exp pulsed electric ﬁeld/or exp electromagnetic ﬁeld/or exp
electrostimulation therapy/or pulsed
electromagnetic.mp. (162787)
8 [limit 15 to (human and english language and randomized
controlled trial and english)] (0)
9 Electric Stimulation Therapy.mp. or exp electrostimulation
therapy/ (147605)
10 Electromagnetics.mp. or exp electromagnetic ﬁeld/ (15534)
11 Electromagnetic Phenomena.mp. or exp electromagnetic
ﬁeld/ (15496)
12 Electromagnetic.mp. or exp electromagnetic ﬁeld/ (28950)
13 electric stimulation therapy.mp. or exp electrostimulation
therapy/ (147605)
14 Electrical stimulation.mp. or exp electrostimulation/ (89918)
15 exp pulsed electric ﬁeld/or exp electromagnetic ﬁeld/or exp
electrostimulation therapy/or pulsed
electromagnetic.mp. (162787)
16 Magnetic Field Therapy.mp. or exp magnetotherapy/ (638)
17 exp electromagnetic ﬁeld/or exp electrostimulation/or exp
electrostimulation therapy/or Pulsed electrical stimulation
treatment.mp. (223854)
18 exp knee osteoarthritis/or Osteoarthritis.mp. or exp osteoar-
thritis/ (76544)
19 Knee osteoarthritis.mp. or exp knee osteoarthritis/ (13867)
20 gonarthrosis.mp. or exp knee osteoarthritis/ (13885)
21 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (250541)
22 18 or 19 or 20 (76774)
23 21 and 22 (1007)
24 limit 23 to (human and english language and randomized
controlled trial and english) (137)
Database: AMED (Allied and Complementary Medicine)
<1985 to April 2012>
1 exp Electric Stimulation Therapy/or Pulsed electrical stimula-
tion treatment.mp. (0)
2 electromagnetics.mp. or exp Electromagnetic Phenomena/
(190)
3 electromagnetic$.tw. (712)
4 exp electric stimulation therapy/ (0)
5 electrical stimulation.tw. (1363)
6 exp Electromagnetic Phenomena/or exp Electric Stimulation
Therapy/or exp Electromagnetic Fields/or pulsed electro-
magnetic.mp. or exp Magnetic Field Therapy/ (221)7 osteoarthritis.mp. or exp Osteoarthritis/or exp Osteoarthritis,
Knee/ (2205)
8 Knee osteoarthritis.mp. or exp Osteoarthritis, Knee/ (595)
9 exp Osteoarthritis/or gonarthrosis.mp. or exp Osteoarthritis,
Knee/ (1612)
10 1 or 2 or 3 or 4 or 5 or 6 (2063)
11 7 or 8 or 9 (2227)
12 10 and 11 (26)
13 limit 12 to (english language and humans and randomized
controlled trial) [Limit not valid; records were retained] (25)
Database: CINAHL (EBSCOHost Search engine) (up to April
2012)
S14 S11 and S12 Limiters e English Language; Human; Random-
ized Controlled Trial; Publication Type: Randomized
Controlled Trial; Language: English
S13 S11 and S12 6
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S10 45
S11 (MH “Osteoarthritis, Knee”) OR “Knee osteoarthritis” 8521
S10 (MH “Magnet Therapy”) OR “Magnetic Field Therapy” 1952
S9 (MH “Electrophoresis, Gel, Pulsed-Field”) OR (MH “Electro-
magnetic Fields”) OR (MH “Electromagneticsþ”) OR “pulsed
electromagnetic ﬁeld” 632
S8 (MH “Electrophoresis, Gel, Pulsed-Field”) OR (MH “Electro-
magnetic Fields”) OR (MH “Electromagneticsþ”) OR “pulsed
electromagnetic ﬁeld” 1674
S7 (MH “Electrophoresis, Gel, Pulsed-Field”) OR (MH “Electro-
magnetic Fields”) OR (MH “Electromagneticsþ”) OR “pulsed
electromagnetic ﬁeld” 1674
S6 (MH “Electromagnetic Fields”) OR (MH “Electromagneticsþ”)
OR (MH “Magnet Therapy”) 1674
S5 (MH “Electromagneticsþ”) OR (MH “Electromagnetic Fields”)
OR “Electromagnetic Phenomena” 1812
S4 (MH “Magnet Therapy”) OR (MH “Electric Stimulationþ”) OR (MH
“Electrical Stimulation, Functional”) OR (MH “Electrical Stimula-
tion,Neuromuscular”) OR “Electric StimulationTherapy” 1226
S3 (MH “Electromagneticsþ”) OR “Electromagnetics” OR (MH “Elec-
tromagnetic Fields”) OR (MH “Bioelectromagnetic Applica-
tions”) 6925
S2 (MH “Electric Stimulationþ”) OR (MH “Electrical Stimulation,
Functional”) OR (MH “Electrical Stimulation, Neuromuscular”)
OR “Pulsed electrical stimulation treatment” 1246
S1 (MH “Magnet Therapy”) OR (MH “Electric Stimulationþ”) OR (MH
“Electrical Stimulation, Functional”) OR (MH “Electrical Stimula-
tion,Neuromuscular”)OR “Electric StimulationTherapy” 6383
Database: Cochrane Central Register of Controlled Trials (up
to April 2012)
#1 knee osteoarthritis:ti,ab,kw in Trials 2265
#2 pulsed electromagnetic ﬁeld:ti,ab,kw in Trials
#3 pulsed electrical stimulation:ti,ab,kw in Trials
#4 (#1 AND (#2 OR #3)) 29References
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